Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

- PMLiVE

FDA clears Takeda’s vedolizumab for inflammatory bowel disease

Entyvio licensed for patients who have not responded to current therapies

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

Bayer symbol

J&J and Bayer unveil new bioincubators

Major pharma companies look to improve collaboration with start-ups

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

- PMLiVE

Xtandi on course for pre-chemo use in prostate cancer

US FDA grants priority review to Medivation and Astellas drug

- PMLiVE

Bayer buys Merck consumer health unit

Continues trend for major pharma deals

- PMLiVE

Bayer outlines some of its digital health needs

Wants to work with startups in areas such as oncology and men's health

- PMLiVE

Bayer’s Nexavar recommended for thyroid cancer in EU

CHMP backs extra indication for cancer drug

- PMLiVE

US jury says Takeda and Lilly must pay $9bn in Actos damages

Court says companies covered up cancer risks of diabetes drug

Novartis building

Novartis replaces execs in Japan after investigation

Finds irregular practices in clinical trials programme

- PMLiVE

Astellas uses animated bladder in campaign

Character in US advertisement for Myrbetriq constantly interrupts a woman with overactive bladder

- PMLiVE

EU approval for Takeda’s schizophrenia drug

Latuda said to have improved side effect profile compared to other treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links